Shanafelt TD, Wang XV, Kay NE, Hanson CA, O’Brien S, Barrientos J, et al. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. New England J Med. 2019;381(5):432–43.

Article  CAS  Google Scholar 

Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. New England J Med. 2018;379(26):2517–28.

Article  CAS  Google Scholar 

Fischer K, Al-Sawaf O, Bahlo J, Fink A-M, Tandon M, Dixon M, et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. New England J Med. 2019;380(23):2225–36.

Article  CAS  Google Scholar 

Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, et al. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. New England J Med. 2023;388(19):1739–54.

Article  CAS  Google Scholar 

Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(1):23–33.

Article  CAS  PubMed  Google Scholar 

Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, et al. Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018;36(19):1973–80.

Article  CAS  PubMed  Google Scholar 

O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17(10):1409-18. This study demonstrates sustained efficacy of ibrutinib in relapsed/refractory CLL harbing a 17p deletion.

Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy. Blood. 2021;138(1):639.

Article  Google Scholar 

Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6(11):3440–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, et al. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat Commun. 2023;14(1):2147.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–60.

Article  CAS  PubMed  Google Scholar 

Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574):525–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D’Rozario J, Assouline S, et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England J Med. 2018;378(12):1107–20.

Article  CAS  Google Scholar 

Munir T, Brown JR, O’Brien S, Barrientos JC, Barr PM, Reddy NM, et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Amer J Hematol. 2019;94(12):1353–63.

Article  CAS  Google Scholar 

Ghia P, Pluta A, Wach M, Lysak D, Šimkovič M, Kriachok I, et al. Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. HemaSphere. 2022;6(12):e801. This study shows superior efficacy and tolerability of acalabrutinib vs. idelalisib-rituximab or bendamustin-rituximab in relapsed/refractory CLL. Up to date, this is the only study prospectively comparing novel drugs of different classes head-to-head in the relapsed disease setting.

Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, et al. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. The New England journal of medicine. 2023;388(4):319-32. Zanubrutinib demonstrates superior tolerability and efficacy in terms of prolonged PFS compared to ibrutinib in relapsed/refractory CLL patients. Notably, this benefit in PFS was maintained in the subgroup of patients with TP53 alterated dissease. Together with the ASCEND trial, these data strongly suggest preferential usage of 2nd-generation BTKI over ibrutinib in CLL, particularly in those with cardiovascular comorbidities.

Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, et al. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2019;37(16):1391–402.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132(23):2446–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. Journal Clin Oncol. 2021;39(31):3441-52. Acalabrutinib demonstrates superior tolerability and similar efficacy compared to ibrutinib in relapsed/refractory CLL patients. Together with the ALPINE trial, these data strongly suggest preferential usage of 2nd-generation BTKI over ibrutinib in CLL, particularly in those with cardiovascular comorbidities.

Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. New England J Med. 2015;374(4):311–22.

Article  Google Scholar 

Brander DM, Seymour JF, Kipps TJ, Ma S, Anderson MA, Choi MY, et al. Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients with Relapsed CLL. Blood. 2019;134(Supplement_1):3036.

Article  Google Scholar 

Kater AP, Harrup R, Kipps TJ, Eichhorst B, Owen CJ, Assouline S, et al. MURANO: Final 7 year follow up and retreatment analysis in venetoclax-rituximab (VenR)-treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Hematol Oncol. 2023;41(S2):239-42. This study suggests promising efficacy of identical retreatment at relapse after fixed-duration venetoclax-rituximab and duration of response beyond 2 years in CLL patients.

Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. New England J Med. 2014;370(11):997–1007.

Article  CAS  Google Scholar 

FDA. Phosphatidylinositol 3-Kinase (PI3K) Inhibitors in Hematologic Malignancies 2022 [cited Available from:https://www.fda.gov/media/157762/download.

Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O’Brien S, Barrientos J, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140(2):112–20.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, et al. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2021;106(9):2364-73. This study shows sustained efficacy and tolerability of acalabrutinib in most CLL patients having discontinued ibrutinib due to adverse events.

Shadman M, Flinn IW, Levy MY, Porter RF, Burke JM, Zafar SF, et al. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Lancet Haematol. 2023;10(1):e35-e45. This study demonstrated sustained efficacy and tolerability of zanubrutinib in CLL patients having discontinued ibrutinib or acalabrutinib due to adverse events.

Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, et al. BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol. 2017;35(13):1437–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Quinquenel A, Fornecker L-M, Letestu R, Ysebaert L, Fleury C, Lazarian G, et al. Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood. 2019;134(7):641–4.

Article  CAS  PubMed  Google Scholar 

Ahn IE, Underbayev C, Albitar A, Herman SEM, Tian X, Maric I, et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017;129(11):1469–79.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thompson MC, Harrup RA, Coombs CC, Roeker LE, Pu JJ, Choi MY, et al. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood Adv. 2022;6(15):4553–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hampel PJ, Call TG, Ding W, Muchtar E, Kenderian SS, Wang Y, et al. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. Amer J Hematol. 2020;95(3):E57–60.

Article  Google Scholar 

Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(1):65–75.

Article  CAS  PubMed  Google Scholar 

Eyre TA, Kirkwood AA, Gohill S, Follows G, Walewska R, Walter H, et al. Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis. Br J Haematol. 2019;185(4):656–69.

Article  CAS  PubMed  Google Scholar 

Anthony RM, Meghan T, John NA, Danielle MB, John MP, Chaitra SU, et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica. 2018;103(9):1511–7.

Article  Google Scholar 

Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, et al. A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. Blood Adv. 2019;3(10):1568–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blombery P, Anderson MA, Gong JN, Thijssen R, Birkinshaw RW, Thompson ER, et al. Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Dis. 2019;9(3):342–53.

Article  CAS  Google Scholar 

Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D, et al. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. Clin Cancer Res. 2020;26(14):3589–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin VS, Lew TE, Handunnetti SM, Blombery P, Nguyen T, Westerman DA, et al. BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Blood. 2020;135(25):2266–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lew TE, Lin VS, Cliff ER, Blombery P, Thompson ER, Handunnetti SM, et al. Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. Blood Adv. 2021;5(20):4054–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hampel PJ, Rabe KG, Call TG, Ding W, Leis JF, Kenderian SS, et al. C